|
1
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Huse JT, Holland E and DeAngelis LM:
Glioblastoma: Molecular analysis and clinical implications. Annu
Rev Med. 64:59–70. 2013. View Article : Google Scholar
|
|
3
|
Cloughesy TF, Cavenee WK and Mischel PS:
Glioblastoma: From molecular pathology to targeted treatment. Annu
Rev Pathol. 9:1–25. 2014. View Article : Google Scholar
|
|
4
|
Burgess DJ: Epigenetics. Dissecting
driving DNA methylations. Nat Rev Cancer. 12:448–449. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cahill N and Rosenquist R: Uncovering the
DNA methylome in chronic lymphocytic leukemia. Epigenetics.
8:138–148. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sulaiman L, Juhlin CC, Nilsson IL, Fotouhi
O, Larsson C and Hashemi J: Global and gene-specific promoter
methylation analysis in primary hyperparathyroidism. Epigenetics.
8:646–655. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mueller S, Phillips J, Onar-Thomas A,
Romero E, Zheng S, Wiencke JK, McBride SM, Cowdrey C, Prados MD,
Weiss WA, et al: PTEN promoter methylation and activation of the
PI3K/Akt/mTOR pathway in pediatric gliomas and influence on
clinical outcome. Neuro-oncol. 14:1146–1152. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zou Z, Anisowicz A, Hendrix MJ, Thor A,
Neveu M, Sheng S, Rafidi K, Seftor E and Sager R: Maspin, a serpin
with tumor-suppressing activity in human mammary epithelial cells.
Science. 263:526–529. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sharma G, Mirza S, Parshad R, Srivastava
A, Gupta SD, Pandya P and Ralhan R: Clinical significance of Maspin
promoter methylation and loss of its protein expression in invasive
ductal breast carcinoma: Correlation with VEGF-A and MTA1
expression. Tumour Biol. 32:23–32. 2011. View Article : Google Scholar
|
|
10
|
McKenzie S, Sakamoto S and Kyprianou N:
Maspin modulates prostate cancer cell apoptotic and angiogenic
response to hypoxia via targeting AKT. Oncogene. 27:7171–7179.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yoshizawa K, Nozaki S, Kitahara H, Kato K,
Noguchi N, Kawashiri S and Yamamoto E: Expression of urokinase-type
plasminogen activator/urokinase-type plasminogen activator receptor
and maspin in oral squamous cell carcinoma: Association with mode
of invasion and clinicopathological factors. Oncol Rep.
26:1555–1560. 2011.PubMed/NCBI
|
|
12
|
Bodenstine TM, Seftor RE, Khalkhali-Ellis
Z, Seftor EA, Pemberton PA and Hendrix MJ: Maspin: Molecular
mechanisms and therapeutic implications. Cancer Metastasis Rev.
31:529–551. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu Y, Alvarez M, Slamon DJ, Koeffler P and
Vadgama JV: Caspase 8 and maspin are downregulated in breast cancer
cells due to CpG site promoter methylation. BMC Cancer. 10(32)2010.
View Article : Google Scholar
|
|
14
|
Alvarez Secord A, Darcy KM, Hutson A,
Huang Z, Lee PS, Jewell EL, Havrilesky LJ, Markman M, Muggia F and
Murphy SK: The regulation of MASPIN expression in epithelial
ovarian cancer: association with p53 status, and MASPIN promoter
methylation: a gynecologic oncology group study. Gynecol Oncol.
123:314–319. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rose SL, Fitzgerald MP, White NO, Hitchler
MJ, Futscher BW, De Geest K and Domann FE: Epigenetic regulation of
maspin expression in human ovarian carcinoma cells. Gynecol Oncol.
102:319–324. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang W and Zhang M: Tissue microarray
analysis of maspin expression and its reverse correlation with
mutant p53 in various tumors. Int J Oncol. 20:1145–1150.
2002.PubMed/NCBI
|
|
17
|
Xie R, Yang H, Xiao Q, Mao F, Zhang S, Ye
F, Wan F, Wang B, Lei T and Guo D: Downregulation of LRIG1
expression by RNA interference promotes the aggressive properties
of glioma cells via EGFR/Akt/c-Myc activation. Oncol Rep.
29:177–184. 2013.
|
|
18
|
Squatrito M, Brennan CW, Helmy K, Huse JT,
Petrini JH and Holland EC: Loss of ATM/Chk2/p53 pathway components
accelerates tumor development and contributes to radiation
resistance in gliomas. Cancer Cell. 18:619–629. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chow LM, Endersby R, Zhu X, Rankin S, Qu
C, Zhang J, Broniscer A, Ellison DW and Baker SJ: Cooperativity
within and among Pten, p53, and Rb pathways induces high-grade
astrocytoma in adult brain. Cancer Cell. 19:305–316. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Stark AM, Schem C, Maass N, Hugo HH, Jonat
W, Mehdorn HM and Held-Feindt J: Expression of metastasis
suppressor gene maspin is reduced in breast cancer brain metastases
and correlates with the estrogen receptor status. Neurol Res.
32:303–308. 2010. View Article : Google Scholar
|
|
21
|
Dzinic SH, Chen K, Thakur A, Kaplun A,
Bonfil RD, Li X, Liu J, Bernardo MM, Saliganan A, Back JB, et al:
Maspin expression in prostate tumor elicits host anti-tumor
immunity. Oncotarget. 5:11225–11236. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Prasad CP, Rath G, Mathur S, Bhatnagar D
and Ralhan R: Expression analysis of maspin in invasive ductal
carcinoma of breast and modulation of its expression by curcumin in
breast cancer cell lines. Chem Biol Interact. 183:455–461. 2010.
View Article : Google Scholar
|
|
23
|
Machtens S, Serth J, Bokemeyer C, Bathke
W, Minssen A, Kollmannsberger C, Hartmann J, Knüchel R, Kondo M,
Jonas U, et al: Expression of the p53 and Maspin protein in primary
prostate cancer: Correlation with clinical features. Int J Cancer.
95:337–342. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Machowska M, Wachowicz K, Sopel M and
Rzepecki R: Nuclear location of tumor suppressor protein maspin
inhibits proliferation of breast cancer cells without affecting
proliferation of normal epithelial cells. BMC Cancer. 14:1422014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cher ML, Biliran HR Jr, Bhagat S, Meng Y,
Che M, Lockett J, Abrams J, Fridman R, Zachareas M and Sheng S:
Maspin expression inhibits osteolysis, tumor growth, and
angiogenesis in a model of prostate cancer bone metastasis. Proc
Natl Acad Sci USA. 100:7847–7852. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bernardo MM, Meng Y, Lockett J, Dyson G,
Dombkowski A, Kaplun A, Li X, Yin S, Dzinic S, Olive M, et al:
Maspin reprograms the gene expression profile of prostate carcinoma
cells for differentiation. Genes Cancer. 2:1009–1022. 2011.
View Article : Google Scholar
|
|
27
|
Kaplun A, Dzinic S, Bernardo M and Sheng
S: Tumor suppressor maspin as a rheostat in HDAC regulation to
achieve the fine-tuning of epithelial homeostasis. Crit Rev
Eukaryot Gene Expr. 22:249–258. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li X, Yin S, Meng Y, Sakr W and Sheng S:
Endogenous inhibition of histone deacetylase 1 by tumor-suppressive
maspin. Cancer Res. 66:9323–9329. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yin S, Lockett J, Meng Y, Biliran H Jr,
Blouse GE, Li X, Reddy N, Zhao Z, Lin X, Anagli J, et al: Maspin
retards cell detachment via a novel interaction with the
urokinase-type plasminogen activator/urokinase-type plasminogen
activator receptor system. Cancer Res. 66:4173–4181. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bailey CM, Khalkhali-Ellis Z, Kondo S,
Margaryan NV, Seftor RE, Wheaton WW, Amir S, Pins MR, Schutte BC
and Hendrix MJ: Mammary serine protease inhibitor (Maspin) binds
directly to interferon regulatory factor 6: Identification of a
novel serpin partnership. J Biol Chem. 280:34210–34217. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Endsley MP, Hu Y, Deng Y, He X, Warejcka
DJ, Twining SS, Gonias SL and Zhang M: Maspin, the molecular bridge
between the plasminogen activator system and beta1 integrin that
facilitates cell adhesion. J Biol Chem. 286:24599–24607. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Blacque OE and Worrall DM: Evidence for a
direct interaction between the tumor suppressor serpin, maspin, and
types I and III collagen. J Biol Chem. 277:10783–10788. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li X, Kaplun A, Lonardo F, Heath E, Sarkar
FH, Irish J, Sakr W and Sheng S: HDAC1 inhibition by maspin
abrogates epigenetic silencing of glutathione S-transferase pi in
prostate carcinoma cells. Mol Cancer Res. 9:733–745. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Latha K, Zhang W, Cella N, Shi HY and
Zhang M: Maspin mediates increased tumor cell apoptosis upon
induction of the mitochondrial permeability transition. Mol Cell
Biol. 25:1737–1748. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Toillon RA, Lagadec C, Page A, Chopin V,
Sautière PE, Ricort JM, Lemoine J, Zhang M, Hondermarck H and Le
Bourhis X: Proteomics demonstration that normal breast epithelial
cells can induce apoptosis of breast cancer cells through
insulin-like growth factor-binding protein-3 and maspin. Mol Cell
Proteomics. 6:1239–1247. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang S, Hao J, Xie F, Hu X, Liu C, Tong
J, Zhou J, Wu J and Shao C: Downregulation of miR-132 by promoter
methylation contributes to pancreatic cancer development.
Carcinogenesis. 32:1183–1189. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sarkar S, Goldgar S, Byler S, Rosenthal S
and Heerboth S: Demethylation and re-expression of epigenetically
silenced tumor suppressor genes: Sensitization of cancer cells by
combination therapy. Epigenomics. 5:87–94. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jaenisch R and Bird A: Epigenetic
regulation of gene expression: How the genome integrates intrinsic
and environmental signals. Nat Genet. 33(Suppl): 245–254. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Maass N, Biallek M, Rösel F, Schem C,
Ohike N, Zhang M, Jonat W and Nagasaki K: Hypermethylation and
histone deacetylation lead to silencing of the maspin gene in human
breast cancer. Biochem Biophys Res Commun. 297:125–128. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Reddy GP, Barrack ER, Dou QP, Menon M,
Pelley R, Sarkar FH and Sheng S: Regulatory processes affecting
androgen receptor expression, stability, and function: Potential
targets to treat hormone-refractory prostate cancer. J Cell
Biochem. 98:1408–1423. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Eitel JA, Bijangi-Vishehsaraei K,
Saadatzadeh MR, Bhavsar JR, Murphy MP, Pollok KE and Mayo LD: PTEN
and p53 are required for hypoxia induced expression of maspin in
glioblastoma cells. Cell Cycle. 8:896–901. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Jiang R, Xia Y, Li J, Deng L, Zhao L, Shi
J, Wang X and Sun B: High expression levels of IKKalpha and IKKbeta
are necessary for the malignant properties of liver cancer. Int J
Cancer. 126:1263–1274. 2010. View Article : Google Scholar
|
|
43
|
Zhang M: PTEN in action: Coordinating with
p53 to regulate maspin gene expression. Cell Cycle. 8:1112–1113.
2009. View Article : Google Scholar : PubMed/NCBI
|
